Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action

A. Barnett, S. Ding, C. Murray, M. Chamberlain, S. Plummer, T. R. J. Evans, I. MacPherson, D. Bissett, C. R. Elcombe, C. R. Wolf

    Research output: Contribution to journalBook/Film/Article reviewpeer-review

    Original languageEnglish
    Pages (from-to)45-46
    Number of pages2
    JournalEJC Supplements
    Issue number7
    Publication statusPublished - 2010

    Cite this